Chenguang Biotech Group 晨光生物
26 significant filings since 31 May 2026: 2 on share pledge, 1 on regulatory action and 12 on guarantee or financial assistance, and 2 other kinds. The latest, on 24 Sep 2026: 关于回购公司股份比例达1%暨回购进展公告. On 13 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to fall by 11.62% to 17.66% from the same period a year earlier.
自 31 May 2026 起有 26 份重大公告：share pledge 2 份、regulatory action 1 份、guarantee or financial assistance 12 份，另有 2 类。最新一份（24 Sep 2026）：关于回购公司股份比例达1%暨回购进展公告。13 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期下降 11.62% 至 17.66%。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥11.61 · Low 最低 ¥10.88 · −2.18% on the previous close of ¥11.45The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 朱会振,舒尚立 | Buy 买入 | 30 Aug 2026 | 4 | — |
| 中邮证券 | 王琦 | Buy 买入 | 27 Aug 2026 | 2 | — |
| 太平洋 | 程晓东 | Buy 买入 | 14 May 2026 | 1 | — |
| 信达证券 | 赵雷 | Unrated | 26 Apr 2026 | 3 | — |
| 华鑫证券 | 孙山山,张倩 | Buy 买入 | 28 Oct 2025 | 1 | — |
| 开源证券 | 张宇光,方勇 | Buy 买入 | 28 Oct 2025 | 1 | — |
| 山西证券 | 冀泳洁,王锐 | Buy 买入 | 20 Oct 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 13 reports. 每行为该券商近十二个月的最新研报；13 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。